K
Kim Rosenthal
Researcher at MedImmune
Publications - 27
Citations - 719
Kim Rosenthal is an academic researcher from MedImmune. The author has contributed to research in topics: Monoclonal antibody & Epitope. The author has an hindex of 11, co-authored 22 publications receiving 359 citations. Previous affiliations of Kim Rosenthal include AstraZeneca.
Papers
More filters
Journal ArticleDOI
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
Yueh Ming Loo,Patrick M. McTamney,Rosalin H. Arends,Michael E. Abram,Anastasia A. Aksyuk,Seme Diallo,Daniel J. Flores,Elizabeth J. Kelly,Kuishu Ren,Richard Roque,Kim Rosenthal,Katie Streicher,Kevin M. Tuffy,Nicholas J. Bond,Owen Cornwell,Jerome Bouquet,Li Cheng,J. Dunyak,Yue Huang,Anton I. Rosenbaum,Venkatesh Pilla Reddy,Hanne Andersen,Robert H. Carnahan,James E. Crowe,Ana I. Kuehne,Andrew S. Herbert,John M. Dye,Helen Bright,Nicole L. Kallewaard,Menelas N. Pangalos,Mark T. Esser +30 more
TL;DR: A combination of two mAbs that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2 are described and AZD7442 is projected to contribute to long-term human protection.
Journal ArticleDOI
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
James C. Geoghegan,Gundo Diedrich,Xiaojun Lu,Kim Rosenthal,Kris Sachsenmeier,Herren Wu,William Dall'acqua,Melissa Damschroder +7 more
TL;DR: The mechanistic activity of a new clinical therapeutic, MEDI9447, a human monoclonal antibody that non-competitively inhibits CD73 activity is described, the first report of an antibody that inhibits an enzyme's function through 2 distinct modes of action.
Journal ArticleDOI
S100A9 Induced Inflammatory Responses Are Mediated by Distinct Damage Associated Molecular Patterns (DAMP) Receptors In Vitro and In Vivo
Bo Chen,Allison L. Miller,Marlon Rebelatto,Yambasu A. Brewah,Daniel C. Rowe,Lori A. Clarke,Meggan Czapiga,Kim Rosenthal,Tomozumi Imamichi,Yan Chen,Chew-Shun Chang,Partha S. Chowdhury,Brian Naiman,Yue Wang,De Yang,Alison A. Humbles,Ronald Herbst,Gary P. Sims +17 more
TL;DR: It is demonstrated that physiological levels of S100A9 homodimers can trigger an inflammatory response in vivo, and despite the capacity of RAGE and TLR4 blockade to inhibit responses in vitro, the response is predominately independent of both these receptors.
Journal ArticleDOI
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
James Brett Case,Samantha Mackin,John M. Errico,Zhenlu Chong,Emily A Madden,Bradley M. Whitener,Barbara Guarino,Michael Schmid,Kim Rosenthal,Kuishu Ren,Ha V. Dang,Gyorgy Snell,Ana Jung,Lindsay Droit,Scott A. Handley,Peter Halfmann,Yoshihiro Kawaoka,James E. Crowe,Daved H. Fremont,Herbert W. Virgin,Yueh Ming Loo,Mark T. Esser,Lisa A. Purcell,Davide Corti,Michael S. Diamond +24 more
TL;DR: In this paper , the authors report on the protection of two monoclonal antibody therapies (S309 and AZD7442) against SARS-CoV-2 Omicron lineage strains (BA.1, BA.2, and BA.1.1).
Journal ArticleDOI
Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody.
Vaheh Oganesyan,Li Peng,Jared S. Bee,John Li,Samuel R. Perry,Frank Comer,Linda Xu,Kimberly E. Cook,Kannaki Senthil,Lori A. Clarke,Kim Rosenthal,Chanshou Gao,Melissa Damschroder,Herren Wu,William Dall'acqua +14 more
TL;DR: The results reveal that MEDI4276's uniqueness is based first on the ability of its 39S paratope to block HER2 homo- or heterodimerization and second on its ability to cluster the receptors on the surface of receptor-overexpressing cells.